Pfizer Inc (PFE)

PFE on New York Consolidated

30.92USD
23 Apr 2014
Price Change (% chg)

$-0.08 (-0.26%)
Prev Close
$31.00
Open
$31.18
Day's High
$31.18
Day's Low
$30.76
Volume
20,427,605
Avg. Vol
28,978,616
52-wk High
$32.96
52-wk Low
$27.12

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company’s diversified global healthcare portfolio includes human... (more)

Overall

Beta: 0.74
Market Cap (Mil.): $198,199.41
Shares Outstanding (Mil.): 6,393.53
Dividend: 0.26
Yield (%): 3.35

Financials

  PFE Industry Sector
P/E (TTM): 18.78 33.12 33.26
EPS (TTM): 1.65 -- --
ROI: 7.49 19.69 18.95
ROE: 14.45 20.39 19.72
Search Stocks

Novartis and GSK trade assets as pharma industry reshapes

ZURICH/LONDON - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition. | Video

22 Apr 2014

Valeant CEO breaks the mold in building drug empire

- At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities.

22 Apr 2014

NEWSMAKER-Valeant CEO breaks the mold in building drug empire

April 22 - At any given time, the acquisitive chief executive of Valeant Pharmaceuticals Inc is brokering multiple deal discussions and eyeing as many as 50 buying opportunities.

22 Apr 2014

UPDATE 4-Novartis and GSK trade assets as pharma industry reshapes

* Deals, plus talk of Pfizer-Astra deal, lift sector shares (Adds details on Lilly animal health unit, updates share movement)

22 Apr 2014

Deals and deal talk among pharmaceuticals lift Britain's FTSE

* FTSE 100 gains 0.9 pct * AstraZeneca surges on report of Pfizer approach * GlaxoSmithKline jumps on asset swap with Novartis (Updates with closing prices, adds technical detail) By Alistair Smout LONDON, April 22 - Corporate activity in the pharmaceutical sector on Tuesday pushed Britain's benchmark stock index to a two-week high and to within sight of a peak for this year. Drugmaker AstraZeneca rose 4.7 percent, with trading volumes in the stock more than three

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1.1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity among drug companies drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 6.7 percent, with trading volumes in the stock over twice its 90-day average

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity in the pharmaceutical sector drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 7.1 percent, with trading volumes in the stock nearly twice their 90-d

22 Apr 2014

Novartis shake-up, Pfizer-AstraZeneca report lifts pharma stocks

LONDON, April 22 - Shares in European drugmakers received a shot in the arm on Tuesday amid a flurry of activity, with Novartis striking a multi-billion dollar deal with GlaxoSmithKline and reports U.S. giant Pfizer had approached Britain's AstraZeneca over a deal.

22 Apr 2014

UK Stocks-Factors to watch on April 22

LONDON, April 22 - Britain's FTSE 100 index is seen opening up by around 29 points, or 0.4 percent, on Tuesday with bid fever set to boost pharmaceutical stocks, according to financial bookmakers. For more on the factors affecting European stocks, please click on

22 Apr 2014

Pfizer agrees to $190 million settlement over generic Neurontin

NEW YORK - Pfizer Inc has agreed to pay $190 million to settle a class action lawsuit alleging the pharmaceutical company took steps to delay market entry of generic versions of its epilepsy drug Neurontin, according to court documents filed on Monday.

21 Apr 2014

Competitors

  Price Change
The Procter & Gamble Company (PG.N) $80.36 -0.25
Johnson & Johnson (JNJ.N) $100.22 +0.04
Novartis AG (NOVN.VX) CHF76.25 -0.15
Merck & Co., Inc. (MRK.N) $57.50 -0.27
Roche Holding Ltd. (ROG.VX) CHF256.20 -0.60
Abbott Laboratories (ABT.N) $38.60 0.00
Bayer AG (BAYGn.DE) €96.83 -0.49
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €77.05 -0.08
AstraZeneca plc (AZN.L) 4,042.50p +82.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Pechala's Reports
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks